Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Ann…

Company to host conference call and webcast today, November 12, at 8:30 am EST/2:30 pm CETIMA402 and IMA401 TCR Bispecifics ...